About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Ohio | 10,042 Studies Near You | Clareo Health

Clinical Trials LocationsOhio

Clinical Trials in Ohio

Discover 10,042 clinical trials near Ohio. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3221-3240 of 10,042 trials

COMPLETEDNA26 miles

Evaluation of Soft Multifocal Lenses in Presbyopic Previous Contact Lens Wearers

NCT06053463

To explore the wear experience in Dailies TOTAL1 Multifocal contact lenses in presbyopic adults who have previously dropped out of contact lens wear.

Jennifer Fogt35 participantsStarted Oct 2023

Columbus, Ohio, United States • Granville, Ohio, United States

Active Not RecruitingPhase 1/232 miles

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Multiple Myeloma

Celgene424 participantsStarted Sep 2019

Denver, Colorado, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +46 more locations

Find Trials by Condition in Ohio

Breast Cancerin Ohio Lung Cancerin Ohio Prostate Cancerin Ohio Colorectal Cancerin Ohio Melanomain Ohio Leukemiain Ohio Lymphomain Ohio Pancreatic Cancerin Ohio Ovarian Cancerin Ohio Brain Cancerin Ohio Diabetesin Ohio

Data from ClinicalTrials.govTerms

Active Not Recruiting32 miles

MIRACLE of LIFE Study

NCT06074601

The goal of this observational study is to develop and validate cell-free RNA-based biomarkers for predicting a variety of adverse pregnancy outcomes in a pregnant person population. The main question it aims to answer are: 1. Can cell-free RNA-based biomarkers predict which pregnant people are at greatest risk of developing adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)? 2. What is the performance of such biomarkers when predicting an adverse pregnancy outcome (e.g., sensitivity, specificity, PPV, NPV, TPR)?

Preterm LaborPreterm BirthPreterm Birth Complication+7 more

Mirvie10,000 participantsStarted Aug 2021

San Diego, California, United States • Orlando, Florida, United States • New Orleans, Louisiana, United States +7 more locations

RECRUITING32 miles

IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry

NCT03536897

This is a prospective, registry trial which will enroll women aged 65 and above with early stage, low risk breast cancer who will be treated with partial mastectomy and intraoperative radiation therapy (IORT). The primary aim is to determine the 5-year risk of in-breast tumor recurrence. Secondary aims include identification of acute- and late-toxicity, cosmetic result, disease-free survival and overall survival.

Mount Carmel Health System168 participantsStarted Feb 2018

Columbus, Ohio, United States

COMPLETEDPhase 232 miles

A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)

NCT03192176

This study determined the effects of different doses and dosing regimens of ESN364 on the frequency and severity of hot flashes. The treatment was administered for 12 weeks to postmenopausal women, aged 40 to 65, suffering at least 50 moderate to severe hot flashes per week.

MenopauseHot Flashes

Astellas Pharma Global Development, Inc.356 participantsStarted Jul 2017

Anniston, Alabama, United States • Birmingham, Alabama, United States • Phoenix, Arizona, United States +48 more locations

COMPLETEDPhase 395 miles

Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

NCT04627025

The primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.

Short Bowel Syndrome

VectivBio AG164 participantsStarted Jan 2021

Los Angeles, California, United States • Naples, Florida, United States • Chicago, Illinois, United States +65 more locations

COMPLETEDPhase 2134 miles

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

NCT02675231

The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies for advanced disease.

Hormone Receptor Positive Breast CancerHER-2 Positive Breast Cancer

Eli Lilly and Company237 participantsStarted May 2016

Bakersfield, California, United States • Fullerton, California, United States • Los Angeles, California, United States +90 more locations

RECRUITINGNA140 miles

ProACT Post-Approval Study

NCT03767595

The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.

Stress Urinary Incontinence

Uromedica145 participantsStarted Feb 2019

Denver, Colorado, United States • Gainesville, Florida, United States • Atlanta, Georgia, United States +3 more locations

RECRUITING140 miles

Regenerative Peripheral Nerve Interfaces to Treat Painful Digit and Hand Neuromas After Amputation

NCT05008185

This study is being done to demonstrate the effectiveness of Regenerative Peripheral Nerve Interfaces (RPNI) surgery in treating symptomatic neuromas of the hand and digits following amputation compared to standard of care using a Prospective, Observational Trial

Medstar Health Research Institute80 participantsStarted Oct 2021

Baltimore, Maryland, United States • Ann Arbor, Michigan, United States

Active Not RecruitingPhase 1/2146 miles

A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

NCT04093349

The purpose of this study is to evaluate the safety, tolerability, and efficacy of a single intravenous infusion of SPK-3006 in adults with clinically moderate, late-onset Pompe disease receiving enzyme replacement therapy (ERT). Participants will be treated in sequential, dose-level cohorts.

Pompe DiseasePompe Disease (Late-onset)Glycogen Storage Disease Type 2+4 more

Spark Therapeutics, Inc.4 participantsStarted Oct 2020

Phoenix, Arizona, United States • Orange, California, United States • Atlanta, Georgia, United States +26 more locations

COMPLETEDPhase 1/2146 miles

Glyburide Advantage in Malignant Edema and Stroke Pilot

NCT01268683

The primary objective of this study is to assess the feasibility of enrolling, evaluating, and treating with glyburide for injection severe anterior circulation ischemic stroke participants, whether or not treated with standard of care intravenous (IV) recombinant tissue plasminogen activator (rtPA). Participants must be between 18-80 years of age, must have a baseline diffusion weighted image (DWI) lesion volume 82 -210 centimeters cubed (cm3), and time from symptom onset to start of study infusion must be ≤10 hour(hr). The secondary objectives are to assess the initial safety and tolerability, and pharmacokinetics (PK) /pharmacodynamics (PD) of glyburide in severe stroke participants, as well as to compare the clinical and magnetic resonance imaging (MRI) outcome data to benchmark data derived from published literature.

Ischemic Stroke

Remedy Pharmaceuticals, Inc.10 participantsStarted May 2011

Chicago, Illinois, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States +1 more locations

COMPLETEDPhase 3275 miles

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

NCT03515837

The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib \[TAGRISSO®\] failure) with T790M-negative mutation tumors, 2) T790M-positive mutation tumors with prior exposure to osimertinib, and 3) first-line osimertinib failure regardless of T790M mutation status. The primary study hypotheses are that the combination of pembrolizumab plus chemotherapy has superior efficacy compared to saline placebo plus chemotherapy in terms of: 1) Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review, and 2) Overall Survival (OS). This study will be considered to have met its success criteria if the combination of pembrolizumab plus chemotherapy is superior to saline placebo plus chemotherapy in terms of PFS or OS. Upon study completion, participants are discontinued and may be enrolled in a pembrolizumab extension study, if available.

Non-small Cell Lung Cancer

Merck Sharp & Dohme LLC492 participantsStarted Jun 2018

Los Angeles, California, United States • Monterey, California, United States • Orange, California, United States +155 more locations

COMPLETEDPhase 4287 miles

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

NCT05531591

The purpose of this study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD), and to test whether treatment-resistant late life depression is associated with declines in memory and attention and brain structure and function.

DepressionDementiaMild Cognitive Impairment+5 more

Centre for Addiction and Mental Health87 participantsStarted Aug 2019

Los Angeles, California, United States • St Louis, Missouri, United States • New York, New York, United States +1 more locations

TERMINATEDPhase 1287 miles

First in Human Study of M1069 in Advanced Solid Tumors

NCT05198349

The main purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and early signs of efficacy of M1069 in participants with advanced solid malignancies.

Metastatic or Locally Advanced Unresectable Solid Tumors

EMD Serono Research & Development Institute, Inc.15 participantsStarted Mar 2022

Hackensack, New Jersey, United States • Nashville, Tennessee, United States • Toronto, Canada

RECRUITINGPhase 1/2306 miles

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC

NCT06681688

This is a multicenter, 2-arm, randomized, prospective study of patients slated for bilateral cataract extraction. One eye will be randomized to the Study Arm, and the fellow eye will be randomized to the Control Arm.

Inder Paul Singh, M.D.94 participantsStarted Jul 2024

Venice, Florida, United States • Racine, Wisconsin, United States

TERMINATEDPhase 1/2322 miles

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

NCT02891161

This is an open label, multi-institutional, single arm study of a phase Ib study, followed by a phase II study of durvalumab with radiation therapy (RT) in patients with urothelial cancer (UC). No randomization or blinding is involved.

Urothelial Cancer

Monika Joshi, MD26 participantsStarted Nov 2016

Iowa City, Iowa, United States • Omaha, Nebraska, United States • New Brunswick, New Jersey, United States +4 more locations

RECRUITINGPhase 1364 miles

A Study of ZN-c3 in Patients With Ovarian Cancer

NCT04516447

This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.

Solid TumorEpithelial Ovarian CancerFallopian Tube Cancer+1 more

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc140 participantsStarted Oct 2020

Aurora, Colorado, United States • Boston, Massachusetts, United States • St Louis, Missouri, United States +21 more locations

COMPLETEDNA391 miles

Feasibility Study of the Reia Vaginal Pessary

NCT04508335

The purpose of this study is to obtain preliminary data on the effectiveness, safety, function, comfort, and patient satisfaction with a novel vaginal pessary design for the use in women who suffer from symptoms of pelvic organ prolapse (POP) and have already opted for non-surgical management. Recruited patients will have Stage II POP or greater and will be current users of a Gellhorn or ring style pessary. Following enrollment, each subject will enter a 1-month wash out period in which they will continue using their current pessary so that baseline subjective and objective data can be collected. They will then be fit with a study pessary and enter a 3-month treatment phase. Comparative, subjective, and objective data will be collected at the conclusion of the study.

Pelvic Organ Prolapse

Reia, LLC78 participantsStarted Nov 2021

Birmingham, Alabama, United States • Cambridge, Massachusetts, United States • Lebanon, New Hampshire, United States +4 more locations

RECRUITINGPhase 1/2402 miles

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

NCT06526923

This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.

Cystic Fibrosis

Spirovant Sciences, Inc.15 participantsStarted Sep 2024

Kansas City, Kansas, United States • Boston, Massachusetts, United States • New York, New York, United States +1 more locations

COMPLETEDPhase 1/2460 miles

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

NCT04079296

The purpose of this study was to evaluate the safety and tolerability and to determine the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) of ASP7517. This study also evaluated the clinical response of ASP7517 as well as other measures of anticancer activity of ASP7517.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome

Astellas Pharma Global Development, Inc.43 participantsStarted Sep 2019

Duarte, California, United States • Pembroke Pines, Florida, United States • New York, New York, United States +13 more locations

PreviousPage 162 of 503Next

Heart Diseasein Ohio